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Ventilator-associated pneumonia (VAP) is pneumonia in
mechanically ventilated patients that develops later than or
at 48 h after the patient has been placed on mechanical
ventilation. VAP is the second most common hospital-ac-
quired infection among pediatric and neonatal intensive
care unit (ICU) (NICU) patients (41, 43). Overall, VAP
occurs in 3 to 10% of ventilated pediatric ICU (PICU)
patients (1, 28). Surveillance studies of nosocomial infec-
tions in NICU patients indicate that pneumonia comprises
6.8 to 32.3% of nosocomial infections in this setting (26, 39,
48). The incidence of VAP is higher in adult ICU patients,
ranging from 15 to 30% (8, 31, 50, 70, 90).
NICU VAP rates vary by birth weight category as well as
by institution. Two large studies are summarized in Table 1.
The most recent National Nosocomial Infection Surveillance
(NNIS) data from 2002 to 2004 show NICU VAP rates ranging
from 1.4 to 3.5 per 1,000 ventilator days (68). In 1998, a cross-
sectional study of hospital-acquired infections in 50 children’s
hospitals was performed by the Pediatric Prevention Network
(88). Of 43 children’s hospitals that returned questionnaires
reporting NICU and PICU surveillance data, the VAP rate by
device days was reported by 19 hospitals, and 12 hospitals
provided VAP rates stratified by birth weight groups (Table 1).
In this cross-sectional survey, VAP rates were highest for the
1,001- to 1,500-g and 1,000-g birth weight categories.
Differences in study methodology and case mix can influence
the reported incidence of VAP (6). Surveillance methods differ
across study institutions, introducing variability into the re-
ported incidence of VAP. The influence of surveillance inten-
sity on the reported prevalence of nosocomial infections is
illustrated by a 41-month surveillance study in a children’s
hospital. Infection control surveillance was conducted twice a
week for the first 2 years of the study and then daily for the
second 2 years of the study through a nursing sentinel sheet.
Those investigators found a 50% increase in the incidence of
* Corresponding author. Mailing address: Pediatric Infectious Dis-
eases, Washington University School of Medicine, Box 8116, St. Louis
Children’s Hospital, One Children’s Place, St. Louis, MO 63110.
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reported nosocomial infections following the introduction of
daily surveillance (39).
NNIS definitions for VAP were revised in 2002, resulting in
a more stringent definition of VAP. Studies of VAP incorpo-
rating these revised definitions reported lower rates of VAP,
making it difficult to know if VAP was previously overdiag-
nosed or is now underdiagnosed. The revised definitions must
also be considered when VAP rates are compared over time.
Applying the Centers for Disease Control and Prevention
(CDC) definitions for VAP in low-birth-weight infants intro-
duces additional complexity in defining the incidence of VAP.
CDC definitions for VAP exist for infants 1 year of age,
but there are no specific definitions for low- or very-low-
birth-weight infants. These patients often have comorbidi-
ties such as bronchopulmonary dysplasia, hyaline membrane
disease, bloodstream infections (BSIs), and necrotizing en-
terocolitis that obscure clinical, laboratory, and radio-
graphic evidence of VAP.
OUTCOMES
VAP is associated with increased morbidity in PICU pa-
tients, specifically, a longer duration of mechanical ventilation.
Fischer et al. (34) performed a prospective cohort study to
determine the delay of extubation attributable to VAP among
neonates and children undergoing repair of congenital heart
disease. Twenty-six of the 272 patients enrolled over a 22-
month period developed VAP (9.6%). VAP diagnosis was
made when the following criteria were met: fever exceeding
38.5°C, tachypnea and/or otherwise unexplained increased ox-
ygen requirement, elevated white blood cell count (15  109
cells/liter), a cultured pathogen from tracheal aspirate together
with a positive gram stain, and increased leukocyte contents,
plus an infiltrate on chest radiographs persisting for 48 h or
more (29). Using a Cox proportional hazards model to control
for complexity of surgery, other respiratory complications, and
secondary surgeries, those investigators found that the median
delay of extubation attributable to VAP was 3.7 days (average
of 5.2 versus 1.5 for patients with and without VAP, respec-
tively). VAP rates increased dramatically for patients intu-
bated for long periods of time. Among patients extubated
within the first 3 days of surgery, only 4% developed VAP,
compared to 40% of postoperative cardiothoracic surgery pa-
tients intubated longer than 30 days (34). Of the 26 VAP cases,
19 occurred within the first 3 to 6 days after surgery.
Presumed VAP is also associated with additional resource
utilization with respect to antibiotic administration. VAP is the
most common reason for the initiation of empirical antibiotics
among PICU patients. A prospective cohort study at an aca-
demic tertiary care center performed in a PICU (n  456)
found that over half (56.6%) of all patients (n  258) received
antibiotics (33). Treatment for suspected VAP comprised 616
of 1,303 (47%) of the antibiotic treatment days. Those authors
reviewed medical records to determine whether patients had
evidence of an alternative explanation for the symptoms attrib-
uted to VAP, such as a viral infection. For 40% of the antibi-
otic days (552/1,303 treatment days), patients were classified as
having no infection (i.e., did not meet clinical criteria as de-
fined by the CDC) or as having a viral infection. Those authors
concluded that an intervention targeted at decreasing anti-
biotic use for VAP would have the greatest impact on antibi-
otic use.
In pediatric populations, the published data are unmatched
for severity of illness and univariate but suggest that pediatric
patients with VAP may have excess mortality and length of
PICU and NICU stay. The European Multicenter Trial exam-
ined the epidemiology of hospital-acquired infections in 20
units (5 PICUs, 7 neonatal units, 2 hematology-oncology units,
and 8 general pediatric units) in eight countries, with a total of
14,675 admissions (710 admission in PICUs) (77). Those in-
vestigators found the infected patients had a longer mean
length of stay in the PICU (26.1  17.3 versus 10.6  6 days;
P  0.001) than uninfected patients. The mortality rate was
10% for PICU patients with nosocomial infections. The mor-
tality and length of stay associated specifically with VAP were
not reported, although VAP accounted for 53% of the noso-
comial infections in PICU patients. Mortality among unin-
fected PICU patients was not reported. Similarly, PICU length
of stay in a 9-month prospective cohort study in an academic
tertiary care center revealed that patients with VAP (n  30)
had a mean PICU length of stay of 27 days versus 6 days for
uninfected patients (n  595) (P  0.001) (28). In that same
study, the mortality rates with and without VAP were 20% and
7%, respectively (P  0.065). Outcomes between patients on
mechanical ventilation for more than 8 days with VAP (n 30)
and those without VAP (n  62) were also compared. PICU
length of stay was longer for VAP patients (27.53  20.09
versus 18.72  35 days), as was hospital length of stay (52.63 
37.43 versus 33.77  49.51 days), but no differences in mortal-
ity rates for VAP (20%) or uninfected patients (21%) were
found. Almuneef et al. (1) determined in a prospective cohort
study (n  361) that PICU lengths of stay with (n  37) and
without (n  324) VAP were longer for patients with VAP
(33.70  30.28 versus 14.66  17.34 days; P  0.001). Sta-
tistically significant differences in mortality rates between
patients with VAP and those without VAP were not found (P 
0.362). Both of those studies performed only univariate anal-
yses to compare mortality rates among patients with and with-
TABLE 1. VAP rates stratified by birth weighta
Study Source
Range (median) of VAP rates by birth weight (g) of:
1,000 1,001–1,500 1,501–2,500 2,500
NNISb 86–102 high-risk nurseries 0.0–8.5 (2.4) 0.0–8.0 (0.0) 0.0–6.1 (0.0) 0.0–3.2 (0.0)
Stoverc 12 NICUs 0.0–21.2 (3.5) 0.0–34.5 (4.9) 0.0–13.7 (1.1) 0.0–6.0 (0.9)
a Range given is the 10th to 90th percentile for NNIS data.
b See reference 68.
c See reference 88.
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out VAP. Multivariate analysis of predictors of mortality
among PICU patients with sufficient numbers of VAP control-
ling for severity of illness both at admission and at the time of
VAP as well as other potential predictors of death is necessary
to determine the true attributable mortality of VAP in pedi-
atric patients.
VAP has also been shown to increase hospital costs. The
cost of VAP was analyzed in a 2-year study of PICU patients
(n  1919) with a single admission (38). The direct cost for
patients with VAP (n  56) was $38,614, and that for patients
without VAP was $7,682. In a multivariate analysis controlling
for other predictors of cost including age, severity of illness,
underlying disease, and ventilator days, VAP was indepen-
dently associated with a direct cost of $30,931 (95% confidence
interval [CI], $18,349 to $82,638) (38). This is a single study
from an academic tertiary care center; further studies are
needed to determine whether the results from this single cen-
ter are generalizable.
Recommendations for Current Practice
and Future Research
Differences in the incidence of VAP occur as a result of the
definitions used, persons doing surveillance, and frequency of
surveillance. Standardization of surveillance methodology and
validation of current definitions against a histopathologic or
microbiologic “gold standard” would make interinstitutional
comparisons meaningful, particularly in light of mandatory
reporting of health care-associated infections. Recent litera-
ture suggests that pediatric VAP is associated with increased
morbidity, antibiotic use, PICU cost, and PICU and hospital
length of stay. Prospective studies using consistent definitions
of VAP and controlling for severity of illness both at admission
and at the time of VAP as well as other possible predictors of
death and length of stay are necessary to define the true at-




The lack of a gold standard for the diagnosis of VAP in both
adults and children makes an interpretation of the literature
complex. The clinical criteria for the diagnosis of VAP have
been established by the NNIS and the CDC (22). Patients who
are mechanically ventilated for more than or equal to 48 h
must have two or more abnormal chest radiographs with at
least one of the following symptoms: new or progressive and
persistent infiltrate, consolidation, cavitation, and/or pneu-
matoceles (in infants 1 year of age). However, in patients
without underlying pulmonary or cardiac disease (respiratory
distress syndrome, bronchopulmonary dysplasia, pulmonary
edema, or chronic obstructive pulmonary disease), one defin-
itive chest radiograph is acceptable. In addition to abnormal
chest radiographs, a patient must have at least one of the
following symptoms: fever (38°C) with no other recognized
cause, leukopenia (4,000 white blood cells [WBC]/mm3) or
leukocytosis (12,000 WBC/mm3), and at least two of the
following criteria: new onset of purulent sputum, change in
character of sputum, increased respiratory secretions, or in-
creased suctioning requirements; new onset of or worsening
cough, dyspnea, or tachypnea; rales or bronchial breath sounds;
and worsening gas exchange (e.g., O2 desaturations [e.g., PaO2/
FiO2 levels of 240], increased oxygen requirements, or in-
creased ventilation demand). The criteria described above may be
used to diagnose VAP in children; however, specific diagnostic
criteria for VAP have been developed for infants 1 year of age
and children 1 and 12 years of age. Infants that are 1 year
old must have worsening gas exchange (oxygen desaturations,
increased oxygen requirements, or increased ventilator demand)
and at least three of the following criteria: temperature instability
with no other recognized cause; new onset of purulent sputum,
change in character of sputum, increased respiratory secretions,
or increased suctioning requirements; apnea, tachypnea, nasal
flaring with retraction of chest wall, or grunting; wheezing, rales,
or rhonchi; cough; and bradycardia (100 beats/min) or tachy-
cardia (170 beats/min). Children1 and12 years of age must
meet at least three of the following criteria: fever (38.4°C or
101.1°F) or hypothermia (37°C or 97.7°F) with no other rec-
ognized cause; leukopenia (4,000 WBC/mm3) or leukocytosis
(15,000 WBC/mm3); new onset of purulent sputum, change in
character of sputum, increased respiratory secretions, or in-
creased suctioning requirements; rales or bronchial breath
sounds; and worsening gas exchange (O2 desaturations [pulse
oximetry of 94%], increased oxygen requirements, or increased
ventilation demand). NNIS/CDC criteria do not require microbi-
ologic confirmation to diagnose pneumonia.
In summary, many of the diagnostic criteria are similar for
the 1-year-old and 1- or 12-year-old age groups. Tem-
perature instability is a diagnostic criterion for the1-year-old
age group; either temperature elevation or hypothermia is a
criterion for the 1- and 12-year-old age group. For the
1-year-old group, cough, bradycardia, tachycardia, nasal flar-
ing, grunting, and wheezing are diagnostic criteria not listed for
the1- or12-year-old age groups, although for the older age
group, dyspnea without further specific definition is a diagnos-
tic criterion. Worsening gas exchange, change in character or
amount of sputum, cough, rales, or bronchial breath sounds
are criteria for diagnosis in all three age groups. We suggest
that a consistent use of the age-specific definitions are pre-
ferred, although we were unable to find any published studies
directly comparing the sensitivity and specificity of the age-
specific definitions to those for any age group.
Clinical definitions for VAP may be applied inconsistently,
and the lack of specific definitions of components of the clin-
ical definition such as worsening gas exchange, oxygen desatu-
rations, increased oxygen requirements, and increased ven-
tilator demand may exacerbate this. Cordero et al. (19)
determined differences in the application of the CDC defini-
tions using NICU patients (n  37) diagnosed with VAP by
interpretation of CDC definitions by infection control practi-
tioners (ICPs) and a positive tracheal aspirate culture. A panel
of neonatologists reviewed the clinical and laboratory evidence
as well as the radiographs. The neonatologists diagnosed VAP
in only seven patients. The neonatologists categorized the
other patients as having asymptomatic airway colonization
(n  12), BSI (n  7), and airway colonization with equivocal
signs of infection (n  11). Among 8 of the 11 patients with
equivocal signs of infection, the general radiologist report
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stated that the radiographic changes were suggestive of VAP;
the neonatologist panel, reviewing the same radiographs, con-
cluded that VAP was unlikely in these patients. Those authors
concluded that an isolated positive tracheal aspirate does not
distinguish between airway colonization and VAP and that
routine radiology reports without definitive clinical and labo-
ratory evidence may be misleading.
Invasive Testing in Adults
NNIS/CDC criteria for VAP do not require microbiologic
confirmation. A brief review of invasive testing to confirm the
diagnosis of VAP in adults will be performed, given the paucity
of literature regarding invasive testing in children. It is unclear
whether the adult experience can be extrapolated to children.
Several studies have examined the accuracy of invasive testing
for the diagnosis of VAP in critically ill adults (Table 2).
Microbiologic examination of specimens obtained from bron-
choalveolar lavage (BAL) or protected specimen brush (PSB)
have an estimated 70% sensitivity and 77% specificity com-
pared to histopathology and/or lung tissue culture (13, 30, 80).
In one of the most comprehensive studies of VAP in me-
chanically ventilated adults, Rouby et al. (80) sought to de-
scribe the histologic and bacteriologic characteristics of human
nosocomial pneumonia and to evaluate the accuracy of pro-
tected mini-BAL for the diagnosis of VAP compared to lung
tissue cultures and lung histology in patients who died while on
mechanical ventilation. Twenty-six patients had both positive
pathology and lung tissue culture; in 20 of these patients, the
BAL and lung tissue culture results were concordant (Fig. 1).
Chastre (13) compared the accuracy of the bronchoscopic
PSB to that of histologic and bacteriologic examinations of
pulmonary specimens in adults (n 26). PSB and lung cultures
were highly correlated (r 0.65; n 28; P 0.001) and higher
in patients not on antibiotics within 1 week before death than
in patients on antibiotics before death (r  0.55; n  33; P 
0.001). Pneumonia was not found by histology or lung tissue
culture when PSB culture organisms were 103 CFU per ml.
PSB cultures with 103 CFU/ml identified all patients with
histologically proven pneumonia. In patients treated with an-
tibiotics, four patients had microorganisms isolated by PSB
with concentrations of 103 CFU/ml not found in the lung
tissue cultures.
Fabregas and colleagues (30) sought to determine the accu-
FIG. 1. Comparison of protected minibronchoalveolar lavage with
histopathology and bacteriology for diagnosing VAP.
TABLE 2. Accuracy of invasive diagnostic techniques for the diagnosis of VAP in adults and childrena
Age group and source
(reference)
No. of






Rouby et al. (80) 26 Protected mini-BAL Histopathology, lung tissue culture 70 69
Chastre et al. (13) 26 PSB Histopathology, lung tissue culture 100 60
Fabregas et al. (30) 25 TBA Histopathology, lung tissue culture 69 92







Gauvin et al. (42) 10 BAL (104 CFU/ml) Expert opinion; 2/3 blinded to BAL
and PSB results
50 80
Bacterial index 5 78 86
ICB 30 95
Endotracheal cultures 90 40
Labenne et al. (60) 29 BAL (104 CFU/ml) (i) Positive pleural fluid culture, (ii)
computed tomography scan with
abscess, (iii) histopathology, (iv) lung
tissue culture, (v) blood and tracheal
aspirate positive for same organism
without other source, (vi) expert
opinion; 2/3 blinded to BAL/PSB
72 88
PSB 69 95
ICB on gram stain and  BAL 79 88
ICB on gram stain and  BAL
and  PSB
90 88
a SE, sensitivity; SP, specificity; TBA, tracheobronchial aspirates; ICB, intracellular bacteria.
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racy of clinical criteria and microbiologic testing for the diag-
nosis of VAP. The clinical pulmonary infection score (CPIS)
was used to compare microbiological criteria, clinical criteria,
and sampling techniques. Lung biopsies were performed for 25
mechanically ventilated patients immediately after death. The
reference standard was the presence of positive histology for
pneumonia or positive lung cultures. Chest X-ray infiltrates
and at least two of three clinical criteria achieved sensitivity
and specificity of 69% and 75%, respectively. The CPIS sensi-
tivity and specificity were 77% and 42%, respectively. Nonin-
vasive and invasive techniques achieved similar results. All
diagnostic techniques combined (PSB, BAL fluid, and pro-
tected BAL fluid) achieved sensitivity and specificity of 85%
and 50%, respectively.
A meta-analysis done in 2005 (n 628) determined whether
invasive testing altered the management and mortality of VAP
in critically ill adults (84). VAP was confirmed bronchoscopi-
cally in 44 to 69% of the patients. Overall, antibiotics were
almost three times as likely to be changed if a bronchoscopy
was performed. In a separate pooled analysis of prospective
uncontrolled trials, alteration in antibiotic prescription oc-
curred 50% (36 to 65%) of the time. To our knowledge, no
similar meta-analyses exist for pediatric populations.
Invasive Testing in Children
A few studies have examined the sensitivity and specificity of
lower airway sampling in PICU patients and found the sensi-
tivity and specificity of BAL (104 CFU/ml) to be 50 to 72% and
80 to 88%, respectively (42, 60) (Table 2). The nonbroncho-
sopic BAL (NB-BAL) has been used in children as an alternative
to fiberoptic BAL to diagnose pneumonia. This procedure is
performed by placing a suction catheter into the endotracheal
tube until resistance is met and then placing and suctioning
back a small amount of sterile normal saline from the lower
airway. The presence of bubbles in the returned fluid is sug-
gestive that a lower airway sample containing surfactant has
been obtained. Quantitative cultures of the fluid are then per-
formed by the microbiology laboratory. This procedure may be
advantageous compared to fiberoptic bronchoscopic tech-
niques because bronchoscopic equipment is not required, a
trained bronchoscopist is not necessary, and the diagnostic
accuracy is comparable to that of fiberoptic techniques (36,
37, 71).
Gauvin et al. (42) performed a 27-month prospective cohort
study of PICU patients suspected of having VAP in a tertiary
academic care center. Of 30 patients, 10 were diagnosed with
VAP and 9 were diagnosed with ventilator-associated trache-
itis by an expert panel. The expert panel was used as the
reference standard; they were given clinical, radiographic, and
microbiologic data but were blinded to the BAL results. A
bacterial index (sum of the log of all species obtained from
BAL) of 5 had the highest correlation with the reference
standard (concordance, 83%; kappa  0.61), a sensitivity of
78%, a specificity of 86%, a positive predictive value of 70%,
and a negative predictive value of 90% (42). Intracellular bac-
teria and gram stain from BAL were specific (95% and 81%,
respectively) but not sensitive (30% and 50%, respectively) for
the diagnosis of pediatric VAP, whereas clinical criteria and
endotracheal cultures were sensitive (100% and 90%, respec-
tively) but not specific (15% and 40%, respectively). That study
concluded that blind BALs with a bacterial index of 5 are the
most reliable method for diagnosing VAP in mechanically ven-
tilated children. The study did not describe what proportion of
patients were on antibiotics or the duration of antibiotic expo-
sure prior to BAL.
Labenne et al. (60) also investigated the sensitivity and spec-
ificity of PSB and BAL in PICU patients with suspected VAP.
The gold standards used by those investigators were a positive
pleural fluid culture, computed tomography scan with pulmo-
nary abscesses, histopathological evidence, positive lung biopsy
(104 CFU/gram), the same bacteria isolated in blood and
endotracheal aspirate without another source, or clinical diag-
nosis using CDC guidelines established independently by two
investigators blinded to PSB/BAL culture results. Of 103 pa-
tients, 29 were diagnosed with VAP, 10 were labeled as “un-
certain,” and 64 were classified as not having VAP. Thirteen of
64 patients with negative PSB and BAL cultures had antibiotics
stopped after 48 h, 25 of 64 had negative cultures, and antibi-
otics were not used at all, and 28 of 38 had a positive tracheal
aspirate culture but negative PSB and BAL, so antibiotics were
discontinued prior to the standard 7-day treatment in that
center. The sensitivity and specificity for BAL fluid culture
were 72% and 88%, respectively. The intracellular bacteria
and the BAL combined had sensitivity and specificity of 79%
and 88%, respectively. Use of PSB culture results in combina-
tion with intracellular bacteria and BAL further increased the
sensitivity and specificity to 90% and 88%, respectively. The
PSB and BAL are effective methods of collecting distal sam-
ples and were helpful in diagnosing VAP. However, a com-
bined diagnostic approach was superior to either one alone.
The safety of the NB-BAL in children has also been deter-
mined by several studies; few adverse experiences (n  18)
have been reported (12, 42, 60, 66, 79). The types of adverse
events were sustained oxygen desaturation requiring increased
ventilatory support (n  11), pneumothorax (n  4), hypoten-
sion (n  2), and significant increase in intracranial pressure
(n  1). Of the 11 patients who experienced sustained oxygen
desaturations, 7 patients were diagnosed with acute respiratory
distress syndrome and saturations in the low 80s before the
procedure was performed. Pneumothorax occurred in patients
less than 1 month of age (n  4). Hypotension occurred in
patients requiring dopamine before the NB-BAL procedure
began.
The safety of NB-BAL and BAL have been examined in a
study evaluating the diagnosis of infectious and interstitial lung
disease in children (n  32) (79). That study found that both
NB-BAL and the BAL were safe, as respiratory rate, heart
rate, and oxygen saturation were monitored during the proce-
dure and a minimum of 6 h afterwards. Patients did not require
increased supplemental oxygen after the procedure, and no
major airway bleeding occurred.
Computerized Surveillance
Recently, a retrospective study was performed to determine
the accuracy of computerized surveillance to detect nosoco-
mial pneumonia in two NICUs over a 2-year period (n  2,932
patients) (46). The automated monitoring system was a natural
language processor, referred to as the Medical Language Ex-
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traction and Encoding system, that converted the electronic
narrative reports to coded descriptions to identify patients with
pneumonia. The automated monitoring system was compared
to diagnosis of VAP by an ICP who performed prospective
surveillance for pneumonia using NNIS definitions. A total of
1,277 patients had chest radiographs. In NICU 1, seven cases
of VAP were identified by the ICP prospective surveillance;
five of the seven cases found by the ICP were also identified by
automated computer surveillance, which flagged an additional
61 patients with possible nosocomial pneumonia. Nine were
considered to be inappropriately flagged by a second indepen-
dent ICP review. The sensitivity and specificity of the compu-
terized surveillance were 71% and 99.8%, respectively. The
positive predictive value was 7.9%, and the negative predictive
value was 99%. In NICU 2, 10 cases of VAP were identified
by the ICP; only 2 of these were flagged by the computer.
Further investigation revealed that 7 of the original 10 cases
were not flagged by the computer because the original chest
radiograph reports could not be found. Eight hundred thirty-
six patients had chest radiographs performed; 84 were flagged
by the computer as VAP. The sensitivity and specificity for
NICU 2 could not be calculated. The findings of that study
indicate that computerized surveillance may be useful in
streamlining the identification of patients with possible VAP
who require a more time-consuming chart review by an ICP.
This system was not linked with microbiology reports. An un-
studied area is computerized surveillance linking both radiol-
ogy and microbiology reports.
Recommendations for Current Practice
and Future Research
The lack of a gold standard plagues all literature regarding
VAP in both adults and children. The current literature sug-
gests that NB-BAL, BAL, and PSB are safe in older children
who do not have severe hypoxemia, increased intracranial
pressure, hemodynamic instability, or bleeding problems and
that invasive testing is sensitive and specific compared to a
reference of expert opinion. Comparison of the clinical defi-
nitions, including the age-specific definitions, with and without
invasive testing against histopathology and/or lung tissue cul-
ture would be a valuable addition to the literature. The feasi-
bility of using NB-BAL in a general patient population and the
effect on antibiotic use remain to be determined.
Computerized surveillance has the potential for consider-
able time savings, particularly if electronic surveillance of the
radiographic reports could be combined with that of microbi-
ology and vital signs and validated against the current practical
gold standard of application of CDC/NNIS definitions by an
experienced clinician who has reviewed the complete medical
record. Additional computerized surveillance studies are nec-
essary to help further understand the impact that computer-
ized surveillance may have on diagnosing pneumonia.
MICROBIOLOGY
Understanding the microbiology of VAP is critical for guid-
ing decisions regarding empirical antibiotic therapy. A retro-
spective cohort study of the microbiologic etiology of VAP in
the ICU setting was performed in three hospital settings: a
large teaching hospital, a community hospital, and a children’s
hospital (5). The most commonly isolated organisms were sim-
ilar across adult and pediatric hospitals: Staphylococcus aureus
(28.4%), Pseudomonas aeruginosa (25.2%), and other gram-
negative bacilli (26.6%). The microbiologies of early-onset and
late-onset infections differed in the adult populations, but this
was not the case in the children’s hospital. Pseudomonas aerugi-
nosa and Staphylococcus aureus were the most commonly iso-
lated organisms in the children’s hospital. Pseudomonas aerugi-
nosa was more common in the PICU than in the NICU (33.3%
versus 17%; P  0.01), while Staphylococcus aureus was more
common in the NICU than in the PICU (38% versus 17.6%;
P  0.001). A prospective cohort study of VAP in the same
NICU was performed. Most of the tracheal isolates from pa-
tients with VAP grew polymicrobial cultures; the organisms
most commonly isolated included Staphylococcus aureus
(23%), Pseudomonas aeruginosa (38.4%), Enterobacter spp.
(38.4%), and Klebsiella spp. (23%) (3). A limitation of these
studies is that the vast majority of isolates were from endotra-
cheal aspirates rather than from invasive sampling of the lower
airway, and thus, the results may represent oropharyngeal
flora.
Two studies reported differences in the microbiologies of
early-onset and late-onset nosocomial pneumonia among chil-
dren. Group B streptococci were most commonly isolated from
infants with maternally acquired pneumonia (31.8%), while
these organisms were rarely isolated in cases of late-onset
pneumonia (1.3%). The frequency of Staphylococcus aureus
increased from 2.4% of maternally acquired cases to 18.7% of
non-maternally-acquired cases of pneumonia, and Pseudomo-
nas aeruginosa frequency increased from 2.9% of maternally
acquired cases to 12.9% of non-maternally-acquired cases of
pneumonia (43).
A 41-month prospective surveillance study of nosocomial
infections in a NICU divided pneumonia into early-onset (on-
set of symptoms within first 48 h of life) and late-onset (onset
of symptoms more than 48 h after birth) infections (98). There
were 35 cases of definite or probable early-onset pneumonia.
In 26 of these cases, potential pathogens were identified: 18
(76.9%) group B streptococci, 1 (3.8%) group F streptococcus,
3 (11.5%) Streptococcus pneumoniae isolates, and 2 (7.7%)
nontypeable Haemophilus influenzae infections. Late-onset
pneumonia occurred in 36 of 358 (10%) neonates who were
ventilated for over 24 h. Cultures were taken from endotra-
cheal tubes or nasopharyngeal secretions for 41 episodes of
late-onset nosocomial pneumonia. The most commonly iso-
lated organisms were coliform spp. (n  18; 43.9%), Pseudo-
monas aeruginosa (n  14; 34.1%), and Staphylococcus aureus
(n  6; 14.6%).
RISK FACTORS FOR VAP IN NICU PATIENTS
In pediatric populations, the pathogenesis of VAP is not well
studied. In adult patients, aspiration of oropharyngeal secre-
tions, inhalation of aerosols containing bacteria, hematoge-
nous spread, and bacterial translocation from the gastrointes-
tinal tract are all considered to be mechanisms of the
development of VAP (89).
Neonates have unique characteristics predisposing them to
nosocomial infections. These patients’ immature immune sys-
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tems place them at increased risk for infection (24). Skin and
mucous membranes are more permeable and are less effective
barriers to infection (47). Abnormal granulocyte migration and
bacterial digestion in these patients have been demonstrated.
Additionally, decreased activity of complement, particularly
complement opsonization, occurs in newborns (40). Lastly,
hypogammaglobulinemia occurs in premature newborns. Ma-
ternal immunoglobulin G (IgG) is transported to the fetus in
the second and last trimesters of pregnancy, and fetal IgG
levels reach maternal levels by term (58). Levels of IgG are
lower in premature newborns, as maternal levels have not yet
been attained. In the initial months following birth, maternal
IgG levels drop, and it takes the infant months to produce
ample levels of IgG and other immunoglobulins.
Low birth weight has been shown to be a risk factor for the
development of nosocomial pneumonia. A 41-month surveil-
lance study demonstrated a significant association between a
birth weight of 1,500 g and a higher rate of nosocomial
pneumonia (48). However, low birth weight may be a marker
for an increased duration of mechanical ventilation. That study
was limited by the lack of a specific control for the duration of
mechanical ventilation. Apisarnthanarak et al. (3) focused on
estimated gestational age (EGA) rather than birth weight in
their 10-month-long case control study of 211 intubated NICU
patients. VAP rates were much higher in babies with an EGA
of 28 weeks (19 VAP cases) than in babies with an EGA of
28 weeks (5 VAP cases) (P  0.001) (3). The VAP rate per
1,000 ventilator days was also higher in babies with an EGA of
28 weeks (6.5/1,000 ventilator days) than in babies with an
EGA of 28 weeks (4.0/1,000 ventilator days) but was not
statistically significant (P  0.34) (3). Not all investigators
found an inverse relationship between birth weight and fre-
quency of nosocomial pneumonia. A prospective surveillance
study of nosocomial infections in seven Brazilian NICUs found
that the rate of nosocomial pneumonia was actually higher in
neonates with birth weights of 1,500 g than in babies with
birth weights of 1,500 g (4.4/1,000 patient days versus 2.8/
1,000 patient days) (72).
Prior BSIs have been identified as a being a risk factor for
VAP in NICU patients. In babies with an EGA of 28 weeks,
history of a prior BSI was the only significant risk factor for the
development of VAP in multivariate analyses after controlling
for the duration of mechanical ventilation (P  0.03). Al-
though none of the cases of VAP were caused by the same
organism as that which caused the BSI, those authors sug-
gested that prior BSI may serve as a surrogate for severity of
illness rather than actually contributing to VAP (3).
The design of the NICU may also have an effect on the
incidence of nosocomial infections and specifically VAP. A
5-year prospective study of nosocomial infections in a NICU
was performed (44). Midway through that study, the NICU
location was moved from cramped quarters adjacent to a busy
medical ward to a new facility. The new nursery had a 50%
increase in staffing and improved infection control features. In
the old nursery, 16 of 492 patients had pneumonia, whereas
in the new nursery, only 1 patient of 419 had pneumonia. While
the new nursery had improved structural infection control
measures such as more space per patient, a large number of
sinks, and a separate isolation room, it is not clear if other
practices of care, such as head-of-bed elevation or suctioning,
changed after the move to the new unit. Those authors did not
report any changes in infection control surveillance or diagno-
sis in the new nursery.
RISK FACTORS FOR VAP IN PICU PATIENTS
Several prospective cohort studies described risk factors for
pediatric VAP. In a prospective cohort study at a tertiary care
center, genetic syndrome (odds ratio [OR], 2.37; 95% CI, 1.01
to 5.46), transport out of the PICU (OR, 8.90; 95% CI, 3.82 to
20.74), and reintubation (OR, 2.71; 95% CI, 1.18 to 6.21) were
all independent predictors of pediatric VAP (28). That study
also found that primary BSIs were associated with the devel-
opment of VAP, as five of the nine patients with primary BSIs
and VAP had the BSI first. Another prospective cohort study
identified prior antibiotic use (OR, 2.45; 95% CI, 1.112 to
5.405), continuous enteral feeding (OR, 2.29; 95% CI, 1.093 to
4.798), and bronchoscopy (OR, 5.04; 95% CI, 1.665 to 15.266)
as being independent predictors of pediatric VAP (1). Immu-
nosuppressant drugs (OR, 4.8; P  0.04), immunodeficiency
(OR, 6.9; P  0.06), and neuromuscular blockade (OR, 11.4;
P  0.002) were also found to be independent predictors in
another prospective cohort study (32). Torres et al. (94) iden-
tified several factors associated with increased risk of develop-
ing VAP: reintubation (OR, 4.95; 95% CI, 3.48 to 7.04; P 
0.000012), gastric aspiration (OR, 5.05; 95% CI, 3.28 to 7.77;
P  0.00018), mechanical ventilation for 3 days (OR, 1.17;
95% CI, 1.15 to 1.19; P  0.015), chronic obstructive pulmo-
nary disease (OR, 1.89; 95% CI, 1.38 to 2.59; P  0.048), and
positive end-expiratory pressure (OR, 1.85; 95% CI, 1.30 to
2.64; P  0.092). In nosocomial pneumonia patients, factors
associated with increased mortality risk were a rapidly fatal
underlying condition (OR, 8.84; 95% CI, 3.52 to 22.22; P 
0.0018), worsening acute respiratory failure from developing
pneumonia (OR, 11.94; 95% CI, 4.75 to 30; P 0.0096), septic
shock (OR, 2.83; 95% CI, 1.41 to 5.78; P  0.016), inappro-
priate antibiotic treatment (OR, 5.81; 95% CI, 2.70 to 12.48;
P  0.02), and non-cardiac-surgery ICU patients (OR, 3.38;
95% CI, 1.70 to 6.71; P  0.08) (78). Medications associated
with the development of VAP are NADP, steroids, and hista-
mine type 2 receptor blockers (28).
Recommendations for Current Practice
and Future Research
Several factors have been identified as being risk factors for
VAP in NICU and PICU patients. Many of these factors re-
flect a risk for aspiration such as that which may occur during
reintubation, physical movement out of the ICU, and bron-
choscopy. In addition, neuromuscular weakness and immuno-
deficiency may predispose a patient to VAP, as does prolonged
mechanical ventilation. A risk stratification system incorporat-
ing preventable and nonpreventable risk factors for pediatric
VAP might assist intensivists in the development of pediatric
VAP prevention bundles and methods for identifying mean-
ingful indicators as a measure of an institution’s success at
VAP prevention. Larger, multicenter, randomized controlled
trials using a standard reference definition of VAP to test
interventions to prevent aspiration in children would be useful.
Testing the efficacy of a standardized assessment of readiness
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to wean mechanical ventilatory support would also be useful in
this patient population, as would a standardized assessment of
pain and the need for sedation and neuromuscular blockade.
PREVENTION
Several recommendations have been given to decrease VAP.
The CDC and Healthcare Infection Control Practices Advisory
Committee suggest using orotracheal tubes (instead of naso-
tracheal tubes) when patients require mechanical ventilation,
changing breathing circuits of ventilators only if they malfunc-
tion or if they are visibly contaminated, and using endotracheal
tubes with dorsal lumens to allow respiratory secretions to
drain (89). There are no recommendations for the preferential
use of sucralfate, histamine 2 receptor antagonists, or antacids
for stress bleeding prophylaxis (89).
Head-of-Bed Elevation
Supine position has been associated with VAP in adult pa-
tients, which is thought to be related to an increase in gastro-
esophageal reflux and aspiration. Semirecumbent positioning
has been demonstrated to decrease surrogate outcomes such
as aspiration and gastroesophageal reflux in adults (16), and
one clinical trial demonstrated a dramatic decrease in the
incidence of confirmed VAP in patients with head-of-bed ele-
vation (5% versus 23%; OR, 6.8; 95% CI, 1.7 to 26.7) (25). The
efficacy of semirecumbent positioning in preventing VAP in
children has not been established. One age- and sex-matched
case control study of nosocomial pneumonia in children found
that head-of-bed elevation did not differ between cases and
controls. That study was limited by small numbers of cases
and controls (n  9 for each group) (10). Additionally, size-
related factors must be considered in the utility of semirecum-
bent positioning in children. For instance, elevating the head
30° is logistically challenging for small pediatric patients such
as infants and toddlers.
In-Line Suctioning
Endotracheal suctioning is used for eliminating bronchopul-
monary secretions from the airway. Traditional open endotra-
cheal suction requires disconnection from the ventilator. This
process has been shown to result in increased intracranial
pressure, increased mean blood pressure, and hypoxia in me-
chanically ventilated children (27, 57). The introduction of a
closed multiuse suction catheter in the 1980s allowed endotra-
cheal suctioning without disconnection from the ventilator. In
critically ill adult populations, closed suction systems have
been shown to result in fewer physiologic disruptions such as
arterial and venous desaturations and arrhythmias (54).
Closed endotracheal suction systems present the potential
for bacterially contaminated secretions to pool in the lumen of
the tube, with reinoculation of the respiratory tract with each
repeated suctioning. On the other hand, a closed system could
potentially decrease environmental contamination of the
respiratory device. Many studies of critically ill adults have com-
pared the incidence of airway colonization and nosocomial
pneumonia in patients on a closed multiuse system to that in
patients on a single-use open suction system. The frequency of
airway colonization has been shown to be significantly more
frequent in patients on the closed suction system (23). How-
ever, studies have not demonstrated an increased frequency of
nosocomial pneumonia in patients on the closed suction sys-
tem (23, 54). Indeed, a more recent prospective randomized
study of 102 ventilated adults demonstrated an increased risk
of VAP for patients with an open suction system compared to
a closed suction system (adjusted risk, 3.5; 95% CI, 1.0 to
12.33) (17). There are currently no CDC recommendations
regarding the preferential use of closed or open suction sys-
tems, nor are there recommendations regarding the frequency
of change for multiuse closed suctioning systems in a single
patient (89).
A single study has compared open and closed suction sys-
tems in critically ill children. Cordero et al. (20) monitored 133
ventilated NICU patients who were alternately assigned to a
closed or open suction system for bacterial airway colonization,
nosocomial pneumonia, BSI, and bronchopulmonary dyspla-
sia. A definition of nosocomial pneumonia required radio-
graphic evidence of “probable” pneumonia (new airspace dis-
ease or a parenchymal process) and positive blood cultures and
tracheal culture for a respiratory pathogen. Colonization pat-
terns from tracheal cultures were comparable between groups,
with gram-positive colonization occurring by the second week
of intubation and gram-negative colonization occurring after
the third week of ventilation. There were no significant differ-
ences in the incidences of VAP or BSIs or mortality between
patient groups. Additionally, the numbers of endotracheal suc-
tions per day, the numbers of reintubations, the incidences and
severities of bronchopulmonary dysplasia, and the numbers of
infants discharged on supplemental oxygen were similar be-
tween groups. Finally, 40 of 44 (91%) NICU nurses judged the
closed suction system to be easier to use, less time-consuming,
and better tolerated by NICU patients.
H2 Blockers/Sucralfate
The acidification of gastric contents is thought to decrease
colonization with potentially pathogenic bacteria. Stress ulcer
prophylactic medications that increase gastric pH, like H2-
antagonists and antacids, may increase colonization with
pathogenic organisms and increase the risk of VAP (18).
Sucralfate is an alternative stress ulcer prophylactic agent that
does not alter gastric pH, and this medication may lower the
risk of VAP while maintaining stress ulcer prophylaxis. Over 20
clinical trials with adults have investigated the risk of VAP
associated with these medications. Of seven meta-analyses of
these clinical trials, four found a significant reduction in the
incidence of VAP in patients treated with sucralfate compared
to patients receiving H2 antagonists. The same effect occurred
in the other three analyses but did not reach statistical signif-
icance. Three of these meta-analyses demonstrated a signifi-
cant reduction in mortality associated with sucralfate therapy
(16).
Two clinical trials compared the risk of VAP with various
methods of stress ulcer prophylaxis in pediatric patients. A
retrospective study included 155 PICU patients who had a
nasogastric tube in place and were mechanically ventilated for
48 h: 54 were given ranitidine, 53 were give sucralfate, and 48
were not on stress ulcer prophylaxis (62). There was no signif-
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icant difference in the incidences of VAP between patients
treated with ranitidine and patients treated with sucralfate
(11.1% versus 7.5%; 2  0.40; P  0.52). That study had
several limitations. Patients were not randomized into study
groups, and patient characteristics differed between patients
given stress ulcer prophylaxis and those who were not given
prophylaxis. The retrospective nature of the study may have
resulted in errors in diagnosing VAP.
A prospective study was performed to study the incidence of
VAP and associated mortality among patients randomized to
one of four groups for stress ulcer prophylaxis in Turkey (101).
That study included 160 PICU patients: 38 received sucralfate,
42 received ranitidine, 38 received omeprazole, and 42 did not
receive prophylaxis. VAP occurred in 70 of 160 (44%) patients,
ranging from 41 to 48% in individual treatment groups. There
was no difference in the incidence of VAP across treatment
groups. The overall mortality rate was 35 of 160 (22%) and did
not differ significantly among treatment groups, ranging from
21 to 23% across groups. The overall incidence of VAP (44%)
in this study was much higher than that reported in other
pediatric studies from referral hospitals (5.1% to 10.2%) (1,
28). It is possible that VAP was overdiagnosed in that study,
although diagnostic criteria used in that study were similar to
criteria used in this country. If VAP was overdiagnosed, this
effect would likely be distributed throughout all study groups.
That study may also have been underpowered to detect differ-
ences in the incidences of VAP among these patient groups.
Both of those studies failed to demonstrate a difference in
the incidence of VAP in patients treated with sucralfate com-
pared to those treated with agents that alter gastric pH. Ad-
ditionally, neither study demonstrated an increased risk of
VAP in patients treated with agents that alter gastric pH com-
pared to that in patients with no treatment. The microbiologies
of infections were similar across treatment groups, and many
infections were caused by organisms that are not likely to be
affected by stress ulcer prophylaxis. It is possible that the study
sizes presented were simply too small to appreciate a signifi-
cant difference in the incidence of VAP, or it is possible that
stress ulcer prophylaxis is not associated with VAP in the
pediatric population. Larger prospective randomized studies of
children are needed to asses the impact of stress ulcer prophy-
laxis on VAP and whether sucralfate has a protective effect
compared to medications that decrease gastric acidity.
Hand Hygiene
Efforts at reducing person-to-person transmission of bacte-
ria are crucial for preventing nosocomial infections. Significant
bacterial contamination of hospital employees’ hands during
routine patient care has been demonstrated (75). The concept
that routine hand washing by health care workers reduces
nosocomial infections is not new, but the first study investigat-
ing the impact of hand hygiene on the rate of hospital-acquired
infections in NICU patients was recently performed (99). A
2-year-long multimodal intervention was instigated, which con-
sisted of formal lectures, written and posted instruction regard-
ing proper hand hygiene technique, covert observation, finan-
cial incentives, and regular feedback of observed hand hygiene
rates. Surveillance of hand washing compliance and nosoco-
mial infections from the pre- and postintervention periods
were compared. The rate of hand hygiene compliance in-
creased from 43% at baseline to 80% during the intervention,
and the rate of respiratory infections decreased from 3.35 to
1.06 per 1,000 patient days (P  0.002) in the pre- and postin-
tervention periods. The two parameters were statistically cor-
related (r  0.385; P  0.014). That study is helpful in
demonstrating an association of hand hygiene and prevention
of nosocomial pneumonia, but it has limitations. The before-
after design of the study makes it difficult to assess if a reduc-
tion in the rate of pneumonia is attributable exclusively to the
increase in hand hygiene. An intervention of this magnitude
may have altered other clinical practices related to the spread
of bacterial contamination, as employees’ awareness of pre-
venting nosocomial infections was increased. Those authors
did point out that no changes in the use of surfactant or suction
procedures occurred during the study period but did not com-
ment on other procedural changes that may have occurred
such as head-of-bed elevation, stress ulcer prophylaxis, or oral
hygiene changes. Additionally, while rates of hand hygiene
compliance remained at 81% during the 16-month postinter-
vention period, it is unclear how sustainable this effect was
after observations were discontinued.
A prospective study of a 3-month-long implementation of an
intervention to decrease rates of nosocomial infection in NICU
patients was undertaken (69). The intervention consisted of
three parts: (i) grouping of all blood-taking tasks to reduce the
number of daily blood draws, (ii) reducing the frequency of
blood investigations after stabilization of acute illness, and (iii)
using an aseptic delivery system of drugs though a central
venous catheter to reduce peripheral intravenous access. The
incidences of nosocomial infection in the NICU between the
1-year preintervention period and the 1-year postintervention
period were compared. VAP rates declined from 3.3/1,000
ventilator days to 1.0/1,000 ventilator days after the interven-
tion. Again, that study was limited by the before-after nature of
the design. Those authors acknowledged that practices regard-
ing mechanical ventilation also changed during the study pe-
riod, as patients were weaned from the ventilator more aggres-
sively and as soon as possible. Earlier weaning may have
contributed to lowering the VAP rates, as prolonged intuba-
tion is a risk factor for VAP in children (62).
The importance of hand hygiene in preventing horizontal
transmission of pathogens among mechanically ventilated pa-
tients was highlighted by a study performed by Sole et al. (86)
to evaluate the proportion of suctioning devices colonized with
pathogenic bacteria and to correlate the bacteria found on
respiratory equipment with those found in patients’ mouths
and sputum. Those investigators found that within 24 h of
changing to new suctioning equipment, 94% of tonsil suction
tubing, 83% of in-line suction tubing, and 61% of distal suction
connectors were colonized with pathogenic bacteria similar to
those found in the patients’ oropharynx and sputum (86).
Selective Decontamination
The impact of using topical antibiotics on tracheostomy sites
on exogenous colonization or infection of the lower airways
has been studied. A 2-year-long prospective observational co-
hort study was performed with 23 children who were treated
with 2% paste of polymyxin E and tobramycin on the trache-
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ostoma four times a day for the first two postoperative weeks
(65). Only 1 of 23 (4%) patients developed exogenous coloni-
zation or infection of the lower respiratory tract, which was
lower than that in historical controls (6/22 [27%]). While top-
ical antibiotics may be useful in preventing exogenous coloni-
zation or infection of the lower airways in children with tra-
cheostoma, the risk of endogenous colonization remains high.
Endogenous colonization or infection occurred in 15 episodes
in 14 of 23 (61%) patients during the 2-week postoperative
period.
Many investigators have studied the efficacy of selective di-
gestive tract decontamination (SDD) in preventing VAP. SDD
traditionally consists of a regimen of topical antimicrobials
applied to the oropharynx and through a nasogastric tube, with
the aim of reducing the burden of pathogenic bacteria in as-
pirated secretions. While the majority of trials have focused
exclusively on the use of topical antimicrobials, many have also
used a short course of intravenous antimicrobial therapy.
Seven meta-analyses of randomized, controlled trials of SDD
in adults all showed a significant reduction in the risk of VAP,
and four of those analyses also demonstrated a significant
reduction in mortality in patients treated with SDD (16). One
recent meta-analysis divided trials into those that used topical
antibiotics alone and those that used a combination of topical
and systemic antimicrobials for the prevention of nosocomial
respiratory infections (61). That analysis included 32 random-
ized, controlled trials including a total of 5,185 adult patients.
A protective effect was demonstrated in trials comparing pa-
tients on a combination of systemic and topical antibiotics with
controls (OR, 0.35; 95% CI, 0.29 to 0.41) and in trials com-
paring patients on topical antibiotics alone with controls (OR,
0.52; 95% CI, 0.43 to 0.63). A significant reduction in mortality
was seen only in trials that used a combination of topical and
systemic therapy (OR, 0.78; 95% CI, 0.68 to 0.89). Mortality
from VAP was not reduced when topical therapy alone was
used (OR, 0.97; 95% CI, 0.81 to 1.16).
Recent evidence suggests that results from some of those
trials may be overly optimistic. A meta-analysis of 32 primary
trials of SDD was performed to assess the impact of study
methodology on results (97). Study methodology was evalu-
ated based on allocation and concealment, patient selection,
patient characteristics, blinding, and definition of nosocomial
pneumonia. That analysis found an inverse relationship be-
tween the methodologic quality and benefit of SDD on the
incidence of pneumonia, suggesting that the benefit of SDD
for the prevention of VAP may be overestimated by many
clinical trials (97).
Studies focusing on the use of SDD to prevent VAP in
children have conflicting results. A prospective study of SDD
in 226 PICU patients randomized study subjects into a treat-
ment (n 116) or control (n 110) group (81). The treatment
group received colistin, tobramycin, and nystatin orally or
through a nasogastric tube every 6 h, and patients were mon-
itored for the development of nosocomial infection in any body
site. There were 87 episodes of any nosocomial infection in 65
of 226 (28.8%) patients. The most common nosocomial infec-
tions were catheter-related bacteremia, sepsis, pneumonia, and
urinary tract infection. The overall incidence of nosocomial
infection across all sites did not differ between treatment and
control groups. However, when infections were studied by
body site, patients in the treatment group had a significantly
lower frequency of pneumonia (2.6% versus 7.2%). In multi-
variate analyses, SDD retained a protective effect against
pneumonia (OR, 0.21; 95% CI, 0.06 to 0.8). There was no
significant difference in overall mortality between the treat-
ment and control groups (six versus five patients). Patients in
that study were randomized and were well matched for most
variables with the exception of severity of illness; the treatment
group had more severely ill patients. This difference in severity
of illness would be expected to skew the results toward the null
hypothesis, but there were actually fewer cases of pneumonia
in the more severely ill group who were treated with SDD.
A prospective, randomized, double-blinded study was per-
formed to determine the efficacy of SDD in preventing noso-
comial infections in severely burned (30% total body surface
area) PICU patients (7). Patients were randomized to the
treatment group (n  11) or control group (n  12). The
treatment group was given a mixture of polymyxin E, tobra-
mycin, and amphotericin B four times daily by nasogastric
tube. No significant differences regarding demographics, un-
derlying conditions, inhalation, injury, or percent of surface
area burned between patient and control groups existed. There
was no difference in the proportion of patients with coloniza-
tion of wounds, feces, nasogastric aspirates, or sputum between
groups at the start of the study or throughout the study. No
significant differences between groups were noted with regard
to the serious complications measured: sepsis, pneumonia, gas-
trointestinal bleeding, respiratory distress syndrome, and mor-
tality. The group treated with SDD had a higher incidence of
diarrhea than the control group (82% versus 17%; P  0.003).
Results from that study suggest that SDD may not prevent
nosocomial infections in pediatric patients. However, that
study was limited by a small sample size (n 23). Additionally,
results of that study may not be generalizable to all PICU
patients, as that study was restricted to burn patients.
A prospective nonrandomized cohort study was performed
to determine the impact of SDD on nosocomial infections in
NICU patients (49). The decision to administer decolonization
was left to attending physicians. Investigators later determined
if patients had received well-performed decolonization (de-
colonization within the first 5 days with oral polymyxin E,
tobramycin, and nystatin), incorrect decolonization (started
after 5 days or less than three drugs used), or no decoloniza-
tion. The incidence of nosocomial respiratory infection was
lower in patients given well-performed (2.5%) or incorrect
(7%) decolonization (P value not given). Interestingly, the
incidence of nosocomial respiratory infection was lowest in
patients who were not decolonized (1%). However, because
patients were not randomized into treatment groups, signifi-
cant underlying differences between groups, including gesta-
tional age, birth weight, NICU length of stay, exposure to
central catheters, and respiratory support, existed. To control
for these differences, investigators performed logistic regres-
sion and found that well-performed selective intestinal decolo-
nization exerted a protective effect toward nosocomial infec-
tions of intestinal origin (OR, 0.17; 95% CI, 0.03 to 0.83). This
group of infections included respiratory tract infections, sepsis,
surgical wound infections, and urinary tract infections. The
investigators did not supply a separate analysis of the impact of
SDD on respiratory infections alone.
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The CDC suggests that health care facilities develop and
implement a comprehensive oral hygiene program for patients
in acute-care settings or residents in long-term care facilities
who are at high risk for health care-associated pneumonia (89).
Fitch et al. (35) demonstrated that an oral care protocol and
scores developed by a dental hygienist could be used by ICU
nurses to improve oral health in critically ill adult patients.
Mean oral inflammation scores were significantly lower after
the implementation of a standard oral care protocol using
toothpaste, antibacterial mouthwash, and oral gel (3.9 [stan-
dard error of the mean, 3.0] versus 12.4 [standard error of the
mean, 2.2]; P  0.03). Those investigators also noted lower
mean scores for oral candidiasis, purulence, bleeding, and
plaque, but the differences were not statistically significant.
The dental hygienist and nurses’ assessments had a high degree
of interrater reliability (kappa  0.64). The scores used in that
study were developed by one of the investigators and reviewed
by other dental faculty members but were not validated in
other patient populations. In addition, those investigators did
not examine the effect of the standard oral care protocol on the
incidence of VAP or bacterial oropharyngeal colonization.
Bergmans et al. (9) performed a prospective, randomized,
placebo-controlled, double-blind study in adult ICU patients
to determine if VAP was preventable by the modulation of
bacterial flora in the oropharynx. Those investigators com-
pared topical prophylaxis to the buccal cavities with 2% each
gentamicin, colistin, and vancomycin (n  87) to an Orabase
placebo group (n  78) (group A) and a second control group
of patients admitted to an ICU where no topical preparation
was used (n  61) (group B). Topical prophylaxis eradicated a
significantly higher proportion of organisms present on admis-
sion in the oropharynx in the treatment group than in either
control group (75% of the treatment group versus 0% in the
placebo group and 9% in the no-preparation ICU group; P 
0.00001). Topical prophylaxis was also effective in eradicating
organisms from the trachea (treatment group, 52%; group A,
22%; group B, 7% [P  0.03]). The incidence of VAP was also
lower in the treatment group (10%) than in the controls (group
A, 31% [P  0.001]; group B, 23% [P  0.04]). That study
concluded that preventing oropharyngeal colonization is pro-
tective against VAP, with an absolute risk reduction of 0.21
(95% CI, 0.09 to 0.33); treating five patients with topical anti-
biotics would prevent one case of VAP. VAP was defined
prospectively using CDC definitions and confirmed with BAL
or PSB. However, it is unclear whether the person who deter-
mined whether the patients had VAP was blinded to the treat-
ment group. In addition, the treatment group received enteral
feeds more frequently than controls, which could alter oropha-
ryngeal flora. The placebo group (group A) was significantly
more likely than the treatment group to receive sucralfate,
another potential confounder of oropharyngeal colonization.
Pineda et al. (73) performed a meta-analysis to determine if
oral chlorhexidine treatment reduced the incidence of VAP.
Four randomized controlled trials including 1,202 patients met
inclusion criteria for the meta-analysis. Patients in the chlor-
hexidine treatment group were less likely to develop VAP than
those in the control group (4% [24 of 587] versus 7% [41 of
615]), although the difference did not reach statistical signifi-
cance (OR, 0.42; 95% CI, 0.16 to 1.06; P  0.07). ICU length
of stay and duration of mechanical ventilation did not differ
between the groups. Mortality was not significantly different
between the two groups (OR, 0.77; 95% CI, 0.28 to 2.11; P 
0.6). The magnitude of the protective OR is striking, as is the
proximity of the CIs to statistical significance, suggesting that
additional studies with larger sample sizes might demonstrate
a significant protective effect from oral chlorhexidine rinses. Of
note, patients in those studies received either a 0.12% chlo-
rhexidine rinse twice a day (n 914) or 0.2% chlorhexidine gel
three times a day (n  288).
A meta-analysis of seven randomized controlled trials (n 
1,650 patients) performed by Chlebicki and Safdar (15) re-
vealed a similar protective effect with a relative risk (RR) of
0.74 (95% CI, 0.56 to 0.96; P  0.02) using a fixed-effects
model and a RR of 0.70 (95% CI, 0.47 to 1.04; P  0.07) using
a random-effects model for patients treated orally with chlor-
hexidine. The risk reduction was even higher in cardiac surgery
patients (RR, 0.41; 95% CI, 0.17 to 0.98; P  0.04) (15).
The Bundle Approach
In December 2004, the Institute for Healthcare Improve-
ment (IHI) challenged hospitals to save 100,000 lives by June
2006 (21). One of the six evidence-based guidelines to be
implemented was the prevention of VAP. The VAP bundle for
adults is to (i) avoid/decrease endotracheal intubation and
duration of mechanical ventilation whenever possible, (ii) use
orotracheal and orogastric tubes to decrease the risk of hospi-
tal-acquired sinusitis, (iii) avoid heavy sedation and neuromus-
cular blockade with depression of cough reflexes, (iv) maintain
endotracheal cuff pressures to greater than 20 cm water, (v)
prevent condensate in tubing from entering the lower respira-
tory tract, (vi) maintain head-of-bed elevation at 30° to 45°,
(vii) maintain oral care, and (viii) maintain hand hygiene
(21, 67).
The team approach using the IHI bundle has been shown to
be successful in reducing VAP (21). The bundle approach has
been used at the Children’s Hospital in Boston and at Vander-
bilt Children’s Hospital. In the latter, an education and inter-
vention termed “ZAP VAP” was put into practice, with their
efforts emphasizing the IHI bundle (21). Prevention included
hand washing, elevating the head of the bed 30° to 45°, mon-
itoring gastric residuals every 4 h to prevent aspiration, pro-
viding aggressive oral care (and documentation) every 2 h,
managing hypopharyngeal secretions, providing in-line endo-
tracheal suction, and providing equipment care. During the
first 6 months of implementation, the time between VAP oc-
currences has nearly tripled.
Educational Interventions
Identifying effective measures for preventing VAP is only as
useful as the proper implementation of these measures in the
clinical setting. Many studies have shown a reduction in rates
of VAP following initiatives to educate health care workers
about the epidemiology of VAP and infection control mea-
sures used to prevent VAP (89). Most of those studies were
performed in the adult ICU setting. A recent educational in-
tervention was performed in an integrated health system, with
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results compared across a large adult teaching hospital, two
community hospitals, and a pediatric teaching hospital (4). The
targeted health care workers were respiratory care practition-
ers and nursing staff working in the ICU setting. This inter-
vention centered on a 10-page self-study module that focused
on multiple aspects of VAP and also included posters, fact
sheets, and in-services for nursing staff and respiratory thera-
pists. VAP rates between the 12-month preintervention period
and the 18-month postintervention period were compared.
Nursing compliance rates were highest among nurses at the
pediatric hospital (100%) and one of the community hospitals
(98.9%). The adult teaching hospital and the other community
hospital had significantly lower compliance rates among nurses
(64.9% and 44.2%; P  0.001). Three hospitals had a signifi-
cant drop in the VAP rates from the preintervention period to
the postintervention period. The VAP rate at the pediatric
hospital fell 38%, from 7.9 episodes to 4.9 episodes per 1,000
ventilator days (P  0.001). The community hospital with no
change in the rate of VAP had the lowest compliance of
respiratory therapists compared to the other three hospital
combined (56.3% versus 95.2%; P  0.001).
Not all lapses in infection control measures result from a
lack of knowledge. A survey of NICU health care workers was
performed to investigate the knowledge, beliefs, and practices
regarding nosocomial infections and infection control mea-
sures (56). The survey revealed some areas in which health
care workers’ actions arose from unawareness of data related
to infection control. For instance, few participants believed
that nosocomial infections were related to health care workers’
rings (40%), artificial fingernails (61%), or long fingernails
(48%). However, that study also revealed some disconnects
between knowledge and practice. Although 96% of respon-
dents believed that using sterile techniques for catheter inser-
tion and care reduces a patient’s risk for BSI, only 67% re-
ported using full sterile barriers at least 76% of the time when
participating in inserting a line. Likewise, 91% of participants
believed gloves are important for preventing the spread of
nosocomial infections, but only 53% reported changing their
gloves in all indicated situations. That study demonstrated the
need for increased educational efforts to bridge the gaps in
knowledge of infection control recommendations. Addition-
ally, the study demonstrated that a lack of knowledge alone
does not account for the lapses in infection control practices in
the NICU studied. The most common barriers to infection
control perceived by respondents included logistics (54%),
time (48%), and lack of supplies (47%).
Interventions that lower rates of VAP may have temporary
effects, with VAP rates eventually rising following the conclu-
sion of the intervention, indicating the need for continuous
reinforcement of interventional measures (55). Factors associ-
ated with noncompliance with hand hygiene exist at the indi-
vidual, group, and institutional levels (74). A proposed frame-
work for the promotion of hand hygiene includes 12 factors: (i)
education, (ii) routine observation and feedback, (iii) engi-
neering controls, (iv) patient education, (v) reminders in the
workplace, (vi) administrative sanctions and rewards, (vii)
change in hand hygiene agents, (viii) promotion of workers’
skin care, (ix) active participation at the individual and insti-
tutional level, (x) maintenance of an institutional safety cli-
mate, (xi) enhancement of individual and institutional self-
efficacy, and (xii) avoidance of overcrowding, understaffing,
and excessive workload (74). The diversity of these factors
emphasizes the need for a multipronged and continuous ap-
proach necessary to maintain high levels of compliance with
infection control measures.
A summary of interventional measures to decrease the inci-
dence of VAP in children is provided in Table 3.
Recommendations for Current Practice
and Future Research
There is scant literature regarding testing the efficacy of
head-of-bed elevation, in-line suctioning, and preferential use
of sucralfate over histamine type 2 receptor antagonists in
pediatric VAP prevention. However, head-of-bed elevation
and other measures to prevent aspiration, a consistent ap-
proach to oral hygiene, meticulous hand hygiene, and regular
assessment of readiness to wean are biologically plausible as
effective VAP prevention measures in children. Further studies
documenting that head-of-bed elevation in children decreases
aspiration and risk of pneumonia as well as determining the
natural history of aerodigestive tract colonization and its rela-
tionship to gastric acidity in children may shed light on the
risk/benefit ratio of sucralfate and/or H2 blockers and the num-
ber needed to treat to prevent pediatric VAP.
VAP TREATMENT
Treatment of suspected VAP is centered on an approach of
initial empirical therapy with broad-spectrum antibiotics fol-
lowed by de-escalation to specific antimicrobial therapy once
culture results are known or discontinuation of antibiotics if
VAP is no longer suspected. The American Thoracic Society
and Infectious Disease Society of America have recently pub-
lished an updated version of their evidence-based guidelines
for the management of VAP in adults (2). Key recommenda-
tions in the new document include the use of early, appropri-
ate, and broad-spectrum antibiotics for empirical therapy; uti-
lization of empirical antibiotics from a different class than
antibiotics that the patient has recently received; judicious use
of combination therapy in hospital-acquired pneumonia; the
potential use of linezolid as an alternative to vancomycin for
VAP caused by methicillin-resistant Staphylococcus aureus
(MRSA); the use of colistin for patients with VAP caused by
carbapenem-resistant Acinetobacter species; the potential use
of aerosolized antibiotics as adjunctive therapy for patients
with VAP caused by certain antibiotic-resistant organisms; de-
escalation of antibiotics based on patients’ culture results and
clinical improvement; and a shorter duration of antibiotics for
patients with uncomplicated health care-associated pneumonia
from bacteria other than nonfermenting gram-negative bacilli.
These guidelines are based on data from clinical trials of hos-
pital-acquired pneumonia in adult patients. There have been
few clinical studies regarding the optimal treatment for VAP in
children.
Empirical Therapy
The importance of prompt initiation of appropriate empir-
ical therapy for suspected VAP has been demonstrated in
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adults, with many studies describing higher mortality in pa-
tients who received delayed appropriate treatment for VAP
(51, 59, 63). However, inappropriate use and overuse of anti-
biotics can lead to increased hospital expenditures and could
potentially promote antibiotic resistance (33, 83). Empirical
antibiotic therapy for suspected VAP accounts for a major
proportion of inappropriate antibiotic use in pediatric patients,
with up to 33% of patients receiving unwarranted antimicro-
TABLE 3. Summary of interventions to prevent VAPa
Intervention and source
(reference) Design Patient description Outcome
Enteral feeds
Almuneef et al. (1) Prospective active
surveillance
361 PICU patients(37 with VAP,
324 without VAP)
Cases had higher frequency of enteral feeds
(48.6% vs 26.8%; OR, 2.58; P  0.006)
Lopriore et al. (62) Retrospective case control 155 PICU patients (13 with VAP,
142 without VAP)
No significant difference between cases and
controls (53.8% vs 43.6%)
Motility agents
Lopriore et al (62) Retrospective case control 155 PICU patients (13 with VAP,
142 without VAP)
Cases had higher frequency of motility agent
use (P  0.05) (association not significant
in logistic regression)
Head-of-bed elevation
Black et al. (10) Matched case control
study
18 PICU patients (9 with VAP,
9 without VAP)
No significant difference between cases and
controls in head-of-bed elevation
Closed vs open suctioning
Cordero et al. (20) Prospective, randomized 133 NICU patients (67 closed,
66 open)
No difference in diagnosis of nosocomial
pneumonia between groups (n  5
patients each)
SDD
Barret et al. (7) Prospective, randomized,
double-blinded
23 burn patients (11 SDD,
12 placebo)
No difference in rates of pneumonia (1 case
in SDD group, 0 in placebo group)
Ruza et al. (81) Prospective, randomized,
nonblinded
226 PICU patients (116 with SDD,
110 without SDD)
SDD protective toward respiratory infection






536 neonates (58 WP SID,
88 IP SID, 392 no SID)
WP SID protective toward NI of intestinal
origin in logistic regression (OR, 0.17;
95% CI, 0.03–0.83).
Stress ulcer prophylaxis
Lopriore et al. (62) Retrospective case control 155 PICU patients (54 ranitidine,
53 sucralfate, 48 no prophylaxis)
No significant difference in upper airway
colonization with GNB, no significant
difference in incidence of VAP
Yildizdas et al. (101) Prospective, randomized,
nonblinded
160 PICU patients (38 sucralfate,
42 ranitidine, 38 omeprazole,
42 no prophylaxis)




Won et al. (99) Prospective study of hand
hygiene campaign
NICU patients admitted during
hand hygiene campaign
Rate of respiratory infections dropped
from 3.35 to 1.06 per 1,000 patient days
(P  0.002)
Babcock et al. (4) Prospective study of
educational intervention
PICU patients at pediatric
teaching hospital
38% reduction in VAP rate from 7.9 to





Ng et al. (69) Prospective surveillance 493 NICU patients (227 before
period, 266 after period)
Non-statistically-significant decrease in VAP
rate from 3.3 to 1.0 per 1,000 ventilator
days (P  0.22)
Oral hygiene
Chlebicki and Safdar (15) Meta-analysis, seven
randomized controlled
trials
1,650 patients total (n  812
	topical chlorhexidine
;
n  838 	comparator
)
Topical chlorhexidine reduced VAP
incidence (RR, 0.74; P  0.02); risk
reduction was even higher in cardiac
surgery patients (RR, 0.41; P  0.04).
Pineda et al. (73) Meta-analysis, four
randomized controlled
trials
1202 patients total (n  587
	chlorhexidine group
;
n  615 	control group
)
Chlorhexidine group less likely to develop
VAP (4%) compared to control group
(7%)(P  0.07); ICU length of stay,
duration of mechanical ventilation, and
mortality not significantly different
Bergmans et al. (9) Prospective, randomized,
double-blinded, placebo
controlled
87 patients (treatment group), 78
patients, (control group A), and
61 patients (control group B)
VAP incidences were less in treatment group
(10%) than in groups A (31%; P  0.001)
and B (23%; P  0.04)
Fitch et al. (35) Longitudinal design,
repeated measures
ICU nurses and dental hygienist Nurses following oral care protocols can help
improve ICU patient oral health
a WP, well performed; IP, incorrectly performed; GNB, gram-negative bacilli; NI, nosocomial infection.
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bial therapy for suspected VAP (33). Prescribing patterns have
also shifted toward more expensive and broader-spectrum an-
tibiotics in hospitalized children in recent years, with the pro-
portion of total antibiotic expenditure used for vancomycin
increasing from 0.2% in 1984 to 17.2% in 1994. Additionally,
broad-spectrum cephalosporins accounted for 17.7% of anti-
biotic expenditures in 1984 and 49.6% in 1994 (96). Thus,
prescribing patterns for empirical therapy for suspected VAP
should maintain a balance between adequately covering pa-
tients who are potentially infected and minimizing unnecessary
and prolonged exposure to antimicrobials.
Infection with potentially antibiotic-resistant organisms ac-
counts for a large proportion of VAP in adults (95). When
selecting empirical therapy, physicians should be aware of the
patient’s risk factors for infection with multidrug-resistant
(MDR) bacteria, the antibiotics that the patient has recently
received, and the local antibiotic resistance patterns. Risk fac-
tors for VAP with MDR pathogens in adults include mechan-
ical ventilation for at least 7 days, prior antibiotic use, and prior
exposure to broad-spectrum antibiotics (imipenem, broad-
spectrum cephalosporins, or fluoroquinolones) (95). In chil-
dren, it has been postulated that patients may be colonized
with organisms from their own preexisting endogenous flora in
response to antibiotic pressure (92). Risk factors for coloniza-
tion with antibiotic-resistant gram-negative organisms in PICU
patients include younger age, increasing PRISM (pediatric risk
of mortality) score, previous PICU admissions, intravenous
antibiotic use in the past 12 months, and exposure to chronic
care facilities (91, 93). Additional special considerations for
the pediatric population include premature infants with an
increased risk of Staphylococcus epidermidis infections and im-
munocompromised patients with an additional need for em-
pirical antifungal therapy (52).
Monotherapy for empirical coverage is recommended for
adult patients with early-onset VAP without risk factors for
infection with MDR pathogens, while combination therapy
should be used for coverage of potential infection with MDR
organisms or late-onset VAP based on a local antibiogram.
Additionally, patients should be treated with antibiotics differ-
ing in class from those that they have recently received in case
colonizing bacteria have developed antibiotic resistance from
previous exposures (2). No consensus guidelines for empirical
coverage of suspected VAP in children exist.
Empirical therapy should be discontinued or altered based on
culture results and clinical status. The fear that negative culture
results may have missed an infection in critically ill children often
leads to prolonged empirical antimicrobial therapy in neonates
(87). A study of late-onset sepsis evaluations in neonates was
undertaken to determine a sufficient time point for the discontin-
uation of empirical therapy. Those investigators found that 99%
of blood cultures were positive within 48 h, and investigators used
this finding as a basis for decreasing empirical coverage from 72 h
to 48 h for suspected late-onset sepsis in neonates. That study
examined cultures from sterile body sites only. Cultures from the
respiratory tract and the vagaries of diagnosing VAP may not
lend themselves to an easily defined time point for the discontin-
uation of empirical therapy in suspected VAP.
Singh et al. (85) used the CPIS to guide the duration of
empirical therapy in adults. Intensive care patients with new-
onset pulmonary infiltrate who were suspected of having pneu-
monia were evaluated at baseline with five of the seven CPIS
items on a scale of 0 to 2 each (temperature, blood leukocytes,
tracheal secretions, oxygenation, and pulmonary radiography).
Patients with a total CPIS of6 were considered to have a low
likelihood of pneumonia and were randomized to receive stan-
dard care as determined by their attending physician or exper-
imental therapy with ciprofloxacin monotherapy. All patients
were reevaluated at 3 days, and of those with CPIS remaining
at 6, 100% of patients in the experimental arm had a cessation
of antimicrobial therapy, compared to 4% of patients in the stan-
dard therapy arm. There was no difference in mortality or length
of stay between treatment groups; antibiotic resistance, superin-
fections, or both occurred more frequently in patients receiving
standard therapy than patients receiving experimental therapy
(35% versus 15%; P  0.017). Replication of these results in
children could offer clinical guidelines for the rapid cessation of
empirical antimicrobial therapy for suspected VAP.
Specific Treatment
Combination therapy exposes patients to multiple antibiotics
and is more expensive; a prompt de-escalation of empirical ther-
apy to more specific antimicrobial therapy should occur once
culture results and susceptibilities are known. Monotherapy is
recommended for patients who are not at risk for infection with
MDR pathogens and for patients infected with gram-positive
pathogens including MRSA. Additionally, patients with severe
VAP should initially be treated with combination therapy but may
be changed to monotherapy if lower respiratory tract cultures do
not identify an antibiotic-resistant pathogen (2). Agents that have
demonstrated efficacy for monotherapy in adult patients infected
with susceptible organisms include fluoroquinolones, carbapenems,
cefepime, and piperacillin-tazobactam (2).
Recent interest surrounding the substitution of linezolid for
vancomycin in the treatment of VAP caused by MRSA has
emerged. A meta-analysis of two prospective, randomized,
double-blind, multicenter, multinational trials in adults with
nosocomial pneumonia comparing clinical cure from linezolid
to vancomycin was performed (100). Patients with MRSA
pneumonia who were treated with linezolid had survival that
was significantly higher than that of patients treated with van-
comycin (80.0% versus 63.5%; P  0.03). Clinical cure rates
were also higher for patients treated with linezolid than those
treated with vancomycin (59.0% versus 35.5%; P 0.01). Both
of these effects remained significant in logistic regression models.
A prospective, randomized, open-label, multicenter, multi-
national trial was performed to compare the efficacy and safety
of linezolid and vancomycin for antibiotic-resistant gram-pos-
itive bacteremia and nosocomial pneumonia in hospitalized
children (53). Among patients with nosocomial pneumonia,
patients randomized to the linezolid group were more often
mechanically ventilated (63.6% versus 10.0%; P  0.011) and
had more multiple-lobe involvement (90.9% versus 50.0%; P
0.038). No significant difference in clinical cure was seen be-
tween patients treated with linezolid and those treated with
vancomycin. However, patients treated with linezolid appeared
to experience a faster resolution of dyspnea/tachypnea/grunt-
ing than patients with vancomycin, with fewer than 40% of
patients receiving linezolid and more than 80% of patients
receiving vancomycin demonstrating these symptoms of VAP
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on day 3 of treatment (P value not given). Additionally, pa-
tients treated with linezolid experienced a shorter mean dura-
tion of total therapy (10.5 days versus 12.8 days; P  0.03) and
intravenous therapy (8.5 days versus 11.3 days; P 0.004). The
frequency of drug-related adverse events was similar between
groups. That analysis was a subset of a larger study, and it
analysis was not powered for nosocomial pneumonia or bac-
teremia. Other subanalyses of this same patient population
have demonstrated the safety of linezolid compared to vanco-
mycin in children (64, 82).
Aerosolized antibiotics have been studied most extensively
in children in the setting of cystic fibrosis. The FDA approval
of tobramycin solution for inhalation is only for maintenance
therapy in patients with cystic fibrosis known to be colonized
with Pseudomonas aeruginosa (76). In two randomized con-
trolled trials, a modest improvement in the forced expiratory
volume in 1 min occurred after 24 weeks of therapy with
tobramycin solution for inhalation; there were significant de-
creases in CFU/ml of Pseudomonas aeruginosa in sputum, de-
creases in hospital admission days, and decreases in numbers
of parenteral antibiotic days for treatment of Pseudomonas
aeruginosa infections. To our knowledge, there are no data
showing that treatment of acute pulmonary infections with
aerosolized antibiotics is beneficial in children. Inhaled amino-
glycosides do produce low but measurable serum concentra-
tions (1 to 4 g/ml). Sputum concentrations vary. No ototox-
icity or nephrotoxicity has been associated with the use of inhaled
aminoglycosides, although many of those studies excluded chil-
dren with serum creatinine levels greater than 2. The potential
disadvantages of use include bronchospasm, increased MICs of
the targeted organism, increased isolation of Candida and As-
pergillus species from sputum, nebulization of microorganisms,
and antibiotic contamination of the environment (76).
Finally, subpopulations of pediatric patients deserve special
consideration. Neurologically impaired children are at in-
creased risk for aspiration or tracheostomy-associated pneu-
monia. The mixed microbiology of these infections, often in-
cluding anaerobic organisms, warrants specific antimicrobial
therapy against likely pathogens. A retrospective study of 57
neurologically impaired children with aspiration or tracheos-
tomy-related pneumonia was performed to evaluate the effi-
cacy of various antimicrobial therapies (11). Children with
either type of pneumonia had better clinical improvement and
microbiological response when treated with agents effective
against penicillin-resistant anaerobic bacteria (ticarcillin-clavu-
lanate or clindamycin) than patients treated with ceftriaxone
(P  0.05 for both tracheostomy-related pneumonia and aspi-
ration pneumonia groups). Although this was a small study
within a focused population, it underscores the need to ac-
count for unique underlying conditions in children that may
predispose them to infections with specific pathogens.
Duration of Therapy
No consensus exists regarding the appropriate duration of an-
timicrobial therapy for VAP in adults, and the appropriate dura-
tion for proven infections in critically ill children has not been
established (45). A multicenter, randomized, controlled trial was
performed using adults with VAP to compare patients treated
with appropriate empirical therapy for 8 days to patients treated
for 15 days (14). There was no difference in mortality or recurrent
infections between groups. Among patients infected with nonfer-
menting gram-negative bacilli, patients treated for 8 days did have
a higher relapse rate (32.8% versus 19.0%; 13.8% risk difference;
90% CI, 7.8% to 19.7%). However, among patients who experi-
enced recurrent infections, patients treated for 8 days were less
likely to become infected with MDR pathogens (42.1% versus
62.0%; P  0.04). These data suggest that limiting treatment of
VAP in patients infected with pathogens other than nonferment-
ing gram-negative bacilli is safe and may decrease the incidence of
reinfection with MDR pathogens.
Recommendations for Current Practice
and Future Research
No consensus guidelines exist for empirical coverage of sus-
pected VAP in children.
Empirical therapy should be discontinued or altered based on
clinical status and culture results, preferably from lower airway
samples. Patients who are severely ill and/or with previous expo-
sure to the health care system should be treated with combination
therapy. Areas for future research in children include the efficacy
of linezolid compared to vancomycin for VAP treatment, the
duration of optimal antibiotic therapy for VAP, and validation of
the CPIS in children as well as its use in treatment decisions.
CONCLUSION
VAP is the second most common hospital-acquired infection
among PICU patients. Empirical therapy for VAP accounts for
approximately 50% of antibiotic use in PICUs. VAP is associ-
ated with an excess of 3 days of mechanical ventilation among
pediatric cardiothoracic surgery patients. The attributable
mortality and excess length of ICU stay of VAP have not been
defined in matched case control studies. VAP is associated
with an estimated $30,000 in attributable cost. Surveillance for
VAP is complex and usually performed using clinical definitions
established by the CDC. Invasive testing via BAL increases the
sensitivity and specificity of the diagnosis. The pathogenesis is
poorly understood in children, but several prospective cohort
studies suggest that aspiration and immunodeficiency are risk
factors. In children, educational interventions and efforts to im-
prove adherence to hand hygiene have been associated with de-
creased VAP rates. More consistent and precise approaches to
the diagnosis of pediatric VAP are needed to better define the
attributable morbidity and mortality, pathophysiology, and appro-
priate interventions to prevent this disease.
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